- Piramal Pharma has exercised its call option to buy the remaining 26% of Yapan Bio, a subsidiary in which it already owns 74%.
- Yapan is a contract development and manufacturing company for vaccines and biologics, focused on process development and early-stage (Phase I/II) clinical supplies.
- The price and the date of transfer are not final yet. Once the deal completes, Yapan becomes a wholly owned subsidiary.
What it means for Piramal Pharma's business
Revenue does not change
- Yapan is already a subsidiary, so its revenue is already counted in Piramal Pharma's consolidated results.
All of Yapan's profit or loss stays with Piramal Pharma
- At 100%, there is no minority shareholder share, so all of Yapan's profit or loss belongs to Piramal Pharma's shareholders.
- Piramal Pharma will have to pay for the 26%; the amount is not yet known.
Full control of a vaccines capability
- Owning all of Yapan lets Piramal Pharma decide on its own how to grow vaccines and biologics work within its contract manufacturing business.
What the filing says
The decision
- A committee of Piramal Pharma's board, acting under powers delegated by the board, approved exercising the call option.
- Piramal Pharma is now in discussions with Yapan's other shareholders to complete the deal.
Terms
- The purchase price and the date the shares change hands are yet to be finalised.
- Piramal Pharma says it will disclose full details once definitive documents are signed and the deal completes.
- Its holding in Yapan will go from 74% to 100%.
Why it matters
What a call option is
- A call option in a shareholder agreement gives one party the right to buy the other shareholders' stake, usually on terms set out in advance.
- Exercising it starts the purchase; the deal still has to be signed and completed.
What the filing does not say
- It gives no price, no valuation and no figures for Yapan's revenue or profit.
What to watch next
- The completion filing, which should give the price and the date of transfer.
Source: Exchange filings
Piramal Pharma: questions
What is Piramal Pharma buying?
The remaining 26% of Yapan Bio, which will take its holding from 74% to 100%, according to its 18 November 2026 filing.
What does buying the rest of Yapan Bio mean for Piramal Pharma's business?
Yapan's revenue is already in Piramal Pharma's results. Full ownership means all of Yapan's profit or loss goes to Piramal Pharma's shareholders, in return for a payment that is not yet fixed.
How much will Piramal Pharma pay?
The filing does not say. The price and the date of transfer are yet to be finalised.
What does Yapan Bio do?
It is a contract development and manufacturing organisation for vaccines and biologics. It handles process development, characterisation and Phase I/II GMP manufacturing.
This page is educational research based on company filings. It is not a recommendation to buy or sell any security or fund, or personalised investment advice. Investments in securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, enlistment with IAASB and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
